Form 4: Sotera Health Executive Rutz Reports Routine Stock Transactions

Sotera Health's President of Sterigenics, Michael P. Rutz, reported a series of routine stock transactions including RSU vestings, tax withholdings, and new RSU grants.

Summary

• Michael P. Rutz, President of Sterigenics at Sotera Health Co., reported multiple transactions on March 2, 2026, related to his beneficial ownership of common stock and derivative securities.
• A total of 3,729 shares, 4,495 shares, and 17,497 shares (totaling 25,721 shares) were withheld by the Issuer at a price of $15.91 per share to satisfy tax withholding obligations upon the vesting of Restricted Stock Units (RSUs) granted in March 2023, March 2024, and March 2025.
• Rutz acquired 14,573 shares of Common Stock due to the vesting of performance-based RSUs granted on March 3, 2025, based on the achievement of specified performance conditions.
• A new grant of 45,223 RSUs was received on March 2, 2026, which will generally vest annually in 60%, 20%, and 20% installments, commencing in March 2027.
• Additionally, 22,612 new performance-based RSUs were granted on March 2, 2026, which will also generally vest annually in 60%, 20%, and 20% installments commencing in March 2027, subject to stock price-related performance conditions.
• Following these reported transactions, Rutz's direct beneficial ownership of Common Stock increased to 484,279 shares, and his direct beneficial ownership of Performance RSUs (derivative securities) increased to 22,612.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, reflecting routine executive compensation and tax-related transactions, with no immediate positive or negative implications for the company's operational or financial performance.

Positives

• Acquisition of 14,573 shares of Common Stock from the vesting of performance-based RSUs, indicating the achievement of performance conditions.
• Grant of 45,223 new Restricted Stock Units (RSUs) on March 2, 2026, increasing future potential beneficial ownership.
• Grant of 22,612 new performance-based RSUs on March 2, 2026, tied to future stock price conditions, offering upside potential.

Negatives

• Disposal of 3,729 shares, 4,495 shares, and 17,497 shares (totaling 25,721 shares) at $15.91 per share to cover tax withholding obligations upon RSU vesting, reducing immediate beneficial ownership.

Future Outlook

Michael P. Rutz's newly granted 45,223 RSUs and 22,612 performance-based RSUs are scheduled to vest annually in 60%, 20%, and 20% installments, commencing in March 2027. The remaining additional performance-based RSUs from a March 2025 grant will also vest in equal annual installments in March 2027 and March 2028, subject to performance conditions.

Industry Context

StockSavvy.ai notes that these transactions represent routine executive compensation activities, typical for publicly traded companies where Restricted Stock Units (RSUs) and performance-based awards are common components of long-term incentive plans. Such filings provide transparency into insider ownership changes but do not typically reflect broader industry trends.

Stakeholder Impact

• Shareholders: Minor impact, as these are routine compensation events that provide transparency on executive ownership.
• Employees: No direct impact mentioned beyond the executive's compensation.
• Customers/Suppliers/Creditors: No direct impact.

Next Steps

• Annual vesting of 45,223 RSUs commencing March 2027.
• Annual vesting of 22,612 performance-based RSUs commencing March 2027, subject to performance.
• Annual vesting of remaining additional performance-based RSUs from March 2025 grant in March 2027 and March 2028, subject to performance.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation activities, including RSU vestings, tax withholdings, and new grants. It does not provide information on the company's financial performance, strategic direction, or market position that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, pending further fundamental analysis of Sotera Health Co.

Keywords

Sotera Health, SHC, Form 4, insider transaction, Restricted Stock Units, RSU vesting, performance-based RSUs, executive compensation, stock ownership, tax withholding